Stan Heptinstall | Academic Influence

Stan Heptinstall's AcademicInfluence.com Rankings

Stan Heptinstall

Political Science

#2720

World Rank

#3187

Historical Rank

Public Administration

#49

World Rank

#56

Historical Rank

political-science Degrees

Download Badge

Political Science

Stan Heptinstall's Degrees

PhD Political Science University of Oxford

Why Is Stan Heptinstall Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Stanley Heptinstall is an Emeritus Professor of the University of Nottingham, Director of Platelet Solutions Ltd , and local government councillor on Nottinghamshire County Council. Previously he was professor of Thrombosis and Haemostasis at the University of Nottingham, retiring in 2011. Professor Heptinstall served as Head of the Division of Cardiovascular Medicine in the School of Clinical Sciences, Faculty of Medicine and Health Sciences.

(See a Problem?)

Stan Heptinstall's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. (2006) (744)
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. (2007) (465)
Randomised double-blind placebo-controlled trial of feverview in migraine prevention (1988) (325)
The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity (2000) (298)
RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF FEVERFEW IN MIGRAINE PREVENTION (1988) (274)
Teichoic Acids and Membrane Function in Bacteria (1970) (215)
DIFFERENTIAL INHIBITION BY LOW-DOSE ASPIRIN OF HUMAN VENOUS PROSTACYCLIN SYNTHESIS AND PLATELET THROMBOXANE SYNTHESIS (1981) (197)
Clopidogrel resistance (2004) (169)
Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin (2002) (162)
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease (2002) (143)
Platelet Aggregation in Whole Blood Determined Using the Ultra-Flo 100 Platelet Counter (1982) (134)
Transfer of Tissue Factor from Platelets to Monocytes: Role of Platelet-Derived Microvesicles and CD62P (2002) (126)
EXTRACTS OF FEVERFEW INHIBIT GRANULE SECRETION IN BLOOD PLATELETS AND POLYMORPHONUCLEAR LEUCOCYTES (1985) (121)
Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood (2001) (110)
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial (2017) (104)
Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups (1987) (102)
A Comparison of the Effects of an Extract of Feverfew and Parthenolide, a Component of Feverfew, on Human Platelet Activity In‐vitro (1990) (99)
Chocolate, Lifestyle, and Health (2009) (99)
Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. (1980) (98)
The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function (2008) (95)
Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz‐Bip.). Estimation of Commercial and Authenticated Feverfew Products (1992) (91)
Anti-platelet therapy: ADP receptor antagonists (2011) (91)
Cocoa Flavanols and Platelet and Leukocyte Function: Recent In Vitro and Ex Vivo Studies in Healthy Adults (2006) (87)
Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. (1989) (79)
Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. (1998) (79)
Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. (2004) (78)
GPIIb-IIIa antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin D. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly. (1998) (70)
Adenine nucleotide metabolism in human blood – important roles for leukocytes and erythrocytes (2005) (69)
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3 (2009) (68)
Platelet Behaviour in Normal Pregnancy, Pregnancy Complicated by Essential Hypertension and Pregnancy-Induced Hypertension (1985) (66)
DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease (2008) (65)
The alanine ester content and magnesium binding capacity of walls of Staphylococcus aureus H grown at different pH values. (1973) (65)
Mechanisms Involved in Adenosine Triphosphate–Induced Platelet Aggregation in Whole Blood (2003) (64)
Parthenolide content of feverfew (Tanacetum parthenium) assessed by HPLC and 1H-NMR spectroscopy (1991) (61)
The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function (2010) (61)
Effects of gelatin-based resuscitation fluids on platelet aggregation. (1998) (61)
A bioassay for inhibition of serotonin release from bovine platelets. (1992) (60)
PGE1 and PGE2 modify platelet function through different prostanoid receptors. (2011) (59)
Compounds extracted from feverfew that have anti‐secretory activity contain an α‐methylene butyrolactone unit (1986) (58)
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro (2001) (53)
A regimen for low-dose aspirin? (1982) (53)
The Use of a Chelating Ion-Exchange Resin to Evaluate the Effects of the Extracellular Calcium Concentration on Adenosine Diphosphate Induced Aggregation of Human Blood Platelets (1976) (53)
Enhanced platelet aggregation and activation under conditions of hypothermia (2007) (51)
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke (2006) (49)
A longitudinal study of platelet behaviour and thromboxane production in whole blood in normal pregnancy and the puerperium (1990) (47)
Multiple electrode aggregometry and P2Y12 antagonists (2008) (47)
Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin (2009) (45)
Progress in the medicinal chemistry of the herb feverfew. (1992) (44)
Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders (2014) (43)
The expression of glycoproteins on single blood platelets from healthy individuals and from patients with congenital bleeding disorders. (1984) (42)
Contribution of platelets to thrombus formation. (1978) (41)
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes (2005) (41)
Neonatal platelet reactivity and serum thromboxane B2production in whole blood: the effect of maternal low dose aspirin (1994) (41)
Sesquiterpene lactones from feverfew, Tanacetum parthenium: isolation, structural revision, activity against human blood platelet function and implications for migraine therapy (1996) (40)
Effects of Ticlopidine Administered to Healthy Volunteers on Platelet Function in Whole Blood (1995) (40)
Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry (2004) (40)
Adenosine Diphosphate Induced Platelet Aggregation and Release Reaction in Heparinized Platelet Rich Plasma and the Influence of Added Citrate (1977) (38)
A Whole Blood Assay of Inhibition of Platelet Aggregation by Glycoprotein IIb/IIIa Antagonists: Comparison with other Aggregation Methodologies (1999) (38)
Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. (1983) (38)
Laboratory investigation of platelet function. (1999) (38)
Differential effects of three radiographic contrast media on platelet aggregation and degranulation: implications for clinical practice? (1998) (37)
The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility. (1985) (36)
Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. (1986) (36)
Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre‐eclampsia (1991) (36)
Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y12 Antagonist (2011) (35)
The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro (2002) (35)
A cross-sectional study of basal platelet intracellular free calcium concentration in normotensive and hypertensive primigravid pregnancies. (1990) (34)
P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist (2003) (34)
Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers (2013) (34)
Prospective double‐blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery (2003) (34)
Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP. (1991) (33)
Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood (2005) (33)
ADP-Induced Platelet Release Reaction in Acute Stroke (1983) (32)
Further studies on the glycerol teichoic acid of walls of Staphylococcus lactis I3. Location of the phosphodiester groups and their susceptibility to hydrolysis with alkali. (1971) (30)
P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP (2011) (30)
A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel (2014) (30)
Formation of platelet-leukocyte conjugates in whole blood. (1997) (29)
Mode of action of P2Y12 antagonists as inhibitors of platelet function (2010) (29)
A randomized placebo‐controlled study of the effect of low dose aspirin on platelet reactivity and serum thromboxane B2 production in non‐pregnant women, in normal pregnancy, and in gestational hypertension (1992) (29)
Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. (1985) (28)
Occurrence of Polymers containing N-Acetylglucosamine l-Phosphate in Bacterial Walls (1968) (27)
MAGNESIUM INFUSION IN ACUTE MYOCARDIAL INFARCTION (1986) (26)
Blood Platelet Behaviour in Mothers and Neonates (1985) (26)
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. (2010) (26)
Platelet Aggregation in Whole Blood: The Role of Thromboxane A2 and Adenosine Diphosphate (1985) (25)
Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood. (1998) (25)
Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood. (1996) (25)
Factors that Contribute to Spontaneous Platelet Aggregation and Streptokinase-Induced Aggregation in Whole Blood (1995) (25)
Pseudo grey platelet syndrome — Grey platelets due to degranulation in blood collected into EDTA (1988) (24)
Glucose increases spontaneous platelet aggregation in whole blood. (1990) (24)
A COMPARISON OF THE ABILITIES OF ACETYLSALICYLIC ACID, FLURBIPROFEN AND INDOMETHACIN TO INHIBIT THE RELEASE REACTION AND PROSTAGLANDIN SYNTHESIS IN HUMAN BLOOD PLATELETS (1979) (24)
Human blood platelet behaviour after inhibition of thromboxane synthetase. (1983) (24)
Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor (2008) (24)
Hemostasis and thrombosis: basic principles and clinical practice, 4th edition (2001) (24)
Effects of cytochalasin H, a potent inhibitor of cytoskeletal reorganisation, on platelet function. (2000) (22)
The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions (2003) (22)
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke (2005) (22)
Platelet-release reaction in myocardial infarction (1980) (22)
Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388) (2015) (22)
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. (2005) (21)
Effects of Prostacyclin and of the Stable Prostacyclin Analogue ZK 36374 on Forearm Blood Flow and Blood Platelet Behaviour in Man (1985) (21)
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders (2018) (21)
Feverfew - An Ancient Remedy for Modern Times? (1988) (20)
SPONTANEOUS PLATELET AGGREGATION IN WHOLE BLOOD: DEPENDENCE ON AGE AND HAEMATOCRIT (1984) (19)
AMOUNTS OF FEVERFEW IN COMMERCIAL PREPARATIONS OF THE HERB (1986) (19)
Contact-induced modulation of neutrophil elastase secretion and phagocytic activity by platelets. (1996) (19)
A cross-sectional study of platelet cyclic AMP in healthy and hypertensive pregnant women. (1991) (19)
AN EXTRACT OP FEVERFEW INHIBITS INTERACTION OP HUMAN PLATELETS WITH COLLAGEN SUBSTRATES (1987) (18)
Effects of anticoagulants used during blood collection on human platelet function. (2004) (18)
The distribution of the glucosyl substituents along the chain of the teichoic acid in walls of Lactobacillus buchneri N.C.I.B. 8007. (1969) (18)
Novel strategies for assessing platelet reactivity. (2017) (17)
Interactions of platelets with Synthocytes, a novel platelet substitute. (2002) (17)
Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphydryl groups. (1988) (17)
Platelet aggregation in whole blood from patients with Glanzmann's thrombasthenia. (1987) (17)
DIFFERENT EFFECTS OF THROMBOXANE SYNTHETASE INHIBITORS ON PLATELETS FROM DIFFERENT INDIVIDUALS (1982) (17)
Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. (1983) (17)
Effects of a Thromboxane Synthetase Inhibitor and a cAMP Phosphodiesterase Inhibitor, Singly and in Combination, on Platelet Behaviour (1986) (16)
Magnesium Modifies the Responses of Platelets to Inhibitory Agents which Act Via cAMP (1995) (16)
UDP-sugars activate P2Y14 receptors to mediate vasoconstriction of the porcine coronary artery (2017) (16)
Spontaneous platelet aggregation in heparinised blood during pregnancy. (1986) (15)
Effects of pluronic F-68 (poloxamer 188) on platelet aggregation in human whole blood. (1996) (15)
Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes (2006) (15)
A Six-Channel Automated Platelet Aggregometer (1975) (15)
Inhibition of the behaviour of human polynuclear leukocytes by an extract of Chrysanthemum parthenium. (1988) (15)
Effects of the co-polymer surfactant, Pluronic F-68, on platelet aggregation in human whole blood. (1997) (15)
Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: A new finding that may influence the design of anti-thrombotic agents (2008) (15)
Blood platelet behaviour during infusion of an Intralipid based intravenous feeding mixture (1982) (14)
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes (2012) (14)
Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. (1989) (14)
Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. (2008) (13)
The Abilities of Human Blood Platelets to Bind Extracellular Calcium and to be Aggregated by Adenosine Diphosphate are Related (1980) (13)
Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. (2004) (13)
The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function (2012) (13)
Inhibition of platelet aggregation by transdermal glyceryl trinitrate. (1994) (13)
Effects of streptokinase and recombinant tissue plasminogen activator on platelet aggregation in whole blood. (1990) (13)
Platelet-release reaction in myocardial infarction. (1980) (12)
Platelet aggregation measured by single-platelet counting and using PFA-100 devices (2018) (12)
Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack (2017) (12)
Feverfew: A Review of Its History, Its Biological and Medicinal Properties, and the Status of Commercial Preparations of the Herb (1998) (12)
Current status of stroke prevention in patients with atrial fibrillation (2005) (11)
Platelet function reduces significantly during the morning (2008) (11)
How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy? (2019) (11)
Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. (1999) (11)
Longitudinal studies of platelet cyclic AMP during healthy pregnancy and pregnancies at risk of pre-eclampsia. (1995) (11)
Platelet Behaviour in Non-Insulin-Dependent Diabetes -Influence of Vascular Complications, Treatment and Metabolic Control (1986) (11)
A Study of the Use of the Thromboxane A2 Antagonist, Sulotroban, in Combination with Streptokinase for Local Thrombolysis in Patients with Recent Peripheral Arterial Occlusions: Clinical Effects, Platelet Function and Fibrinolytic Parameters (1993) (11)
‘VASPFix’ for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists (2013) (11)
Identity of Saturable Calcium-Binding Sites on Blood Platelets and Their Involvement in Platelet Aggregation (1988) (11)
PGE2 reverses Gs-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-Gs-mediated inhibition of platelet aggregation by interaction with EP4 receptors (2012) (11)
A randomized placebo‐controlled study of the effect of low dose aspirin on platelet reactivity and serum thromboxane B2 production in non‐pregnant women, in normal pregnancy and in gestational hypertension (1993) (10)
Pluronic F-68 inhibits agonist-induced platelet aggregation in human whole blood in vitro. (1998) (10)
Comparison of Extraction Procedures for Parthenolide inTanacetum parthenium (1996) (10)
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y 12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes (2007) (10)
Changes in plasma ionised calcium within 24 hours of trauma in patients infused with the calcium containing colloid Haemaccel during fluid resuscitation. (1997) (10)
Evidence that Adenosine Diphosphate Can Activate Adenylate Cyclase via Conversion to Adenosine in Platelet-rich Plasma Containing Magnesium (1998) (9)
Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK-852 and ARL 66096. (1996) (9)
Value of Platelet Activation Markers as Prothrombotic Risk Indicators (2007) (9)
The teichoic acids of Micrococcus sp. 24. (1971) (9)
Activation of leukocytes in whole blood samples by N-formyl-methionyl-leucyl-phenylalanine (FMLP) enhances platelet aggregability but not platelet P-selectin exposure and adhesion to leukocytes. (1998) (9)
Correlation between platelet behaviour and cold-induced vasoconstriction in man, and the effects of epoprostenol infusion. (1984) (9)
Investigations on spontaneous aggregation and platelet responses to streptokinase and to adrenaline during pregnancy. (1994) (9)
ADP-induced platelet aggregation and actin polymerization. Involvement of GpIIb/IIIa and the effect of Mg2+. (1995) (9)
Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. (2018) (9)
PAMFix, a fixative developed to enable remote platelet function testing: uses and applications (2015) (8)
Arachidonic acid metabolism by peripheral blood cells in psoriasis (1986) (8)
Feverfew--an antithrombotic drug? (1988) (8)
Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre‐eclampsia (1992) (8)
Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis (2008) (8)
Monoamine Oxidase Activity in Diabetes (1983) (8)
Changes in G-Actin after Platelet Activation in Platelet Rich Plasma (1992) (7)
An observational study investigating the effect of platelet function on outcome after colorectal surgery. (2015) (7)
Enhanced Spontaneous Platelet Aggregation and red Blood Cell Fragility in Whole Blood Obtained from Patients with Diabetes. (1991) (6)
Circulating Microparticles in Patients with Symptomatic Carotid Disease Are Related to Embolic Plaque Activity and Recent Cerebral Ischaemia (2019) (6)
Effects of an extract of feverfew on endothelial cell integrity and on cAMP in rabbit perfused aorta (1988) (6)
Platelet-monocyte interaction and GPIIb/IIIa blockade (2004) (6)
Effects of an extract of feverfew (Tanacetum parthenium) on arachidonic acid metabolism in human blood platelets. (1988) (6)
Platelet aggregation and intracellular calcium mobilisation responses are enhanced by cyclosporin A but not by pimecrolimus (SDZ ASM 981). (2002) (6)
The composition of the platelet cytoskeleton following activation by ADP: effects of various agents that modulate platelet function. (1996) (5)
Platelet-platelet Contact and Thromboxane A(2) Contribute to Actin Polymerization in Platelets Stimulated with ADP. (1994) (5)
Original article: Effects of Raised Extracellular Magnesium on Platelet Reactivity. (1995) (5)
Actin polymerization and depolymerization in relation to platelet shape change, aggregation and disaggregation. (1996) (5)
The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals. (1985) (5)
A New Journal called Platelets. (1990) (5)
Influence of substances affecting cell sulfhydryl/disulfide status on adherence of human monocytes. (1990) (5)
Effects of diamide and iodoacetamide on the expression of the glycoprotein IIb/IIIa complex on blood platelets. (1985) (5)
A Remote Assay for Measuring Canine Platelet Activation and the Inhibitory Effects of Antiplatelet Agents (2017) (4)
Baseline characteristics of the 3096 patients recruited into the ‘Triple Antiplatelets for Reducing Dependency after Ischemic Stroke’ trial (2017) (4)
Measurements of the G-/F-actin equilibrium in ADP-stimulated human platelets. (1991) (4)
Aspirin and dazoxiben as inhibitors of platelet behaviour: modification of their effects by agents that alter cAMP production. (1986) (4)
Unexpected changes in the catecholamine content of platelets and plasma during exercise. (1999) (4)
Platelet Reactivity In Vitro in Relation to Thromboxane in Healthy Pregnancy (1996) (4)
Novel Fluorosurfactants For Perfluorochemical Emulsification (1997) (4)
Studies on platelets before and after stroke in a patient with essential thrombocythaemia (1988) (4)
Haematology, ethnography, and thrombosis. (1987) (4)
ADP-induced P-selectin expression on platelets as a predictor of successful thrombolysis. (1996) (3)
Measurement of platelet activation and adhesion to leukocytes during haemodialysis. (1998) (3)
Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation. (1986) (3)
Properties of blood platelets that may be relevant to atherogenesis. (1984) (3)
Antiplatelet Agents: Current and Novel (2013) (3)
Antiplatelet therapy and vascular disease. (1994) (3)
Efficacy of dipyridamole as prophylaxis for stroke and the added value of dipyridamole in combination with aspirin. (1996) (3)
Novel fluoro-surfactants for perfluorochemical emulsification. Effects on aggregation of human platelets in vitro and possible applications as anti-thrombotic agents. (1997) (3)
Sulfhydryl/disulfide-status of blood platelets--a target for pharmacological intervention? (1989) (3)
Platelet activation by an extracellular adherence protein from Staphylococcus aureus acting via modulation of sulfhydryl groups on platelets. (2012) (3)
[Cellular chemiluminescence of activated phagocytes of whole blood]. (1989) (3)
[The effect of high glucose concentrations on the osmotic and mechanical resistance of human erythrocytes]. (1989) (3)
Should critical care patients receive or remain on treatment with antiplatelet drugs? (2010) (2)
Inhibition Of Thromboxane Synthesis And Of Arachidonate- Induced Platelet Behaviour In Platelets From Different Individuals (1981) (2)
Platelet behaviour and vascular disease. (1980) (2)
The Effect Of Low Dose Aspirin On Human Venous Prostacyclin Production And Platelet Thromboxane Synthesis (1981) (2)
SIMILARITY BETWEEN PLATELET AND BLOOD-VESSEL REACTIVITY (1985) (2)
Examination of glycoproteins on intact blood platelets by using monoclonal antibodies and the fluorescence-activated cell sorter (1985) (2)
BOW CAN WE INHIBIT 5HT-INDUCED PLATELET AGGREGATION AND WHY SHOULD WE BOTHER? (1987) (2)
Leukocytosis, vascular disease, and adenine nucleotide metabolism. (2005) (2)
Abstract 3292: AZD6140 Exerts Greater Inhibition of Platelet Aggregation than Clopidogrel in Patients with Stable Atherosclerotic Disease or Unstable Coronary Disease (2006) (2)
The platelet aggregating activity of 2,3-diphosphoglycerate may be caused by ADP impurity. (1991) (2)
PO-27 Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis (2007) (2)
Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel (2020) (2)
The value of anti-platelet treatment in vascular diseases. (1990) (1)
Actin determinations in unstimulated and stimulated platelets in platelet rich plasma (1992) (1)
Diamide induces reversible aggregation of human blood platelets. (1985) (1)
How important is it to keep taking the aspirin? (2013) (1)
Extracellular Calcium And Platelets (1981) (1)
Abstracts presented at the Nottingham Platelet Conference, Platelets – Past, Present and Future (2010) (1)
Effects of combination of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation (1986) (1)
Bath, Philip M. and May, Jane and Heptinstall, Stan (2018) Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets (2018) (1)
The influence of anticoagulants and extracellular divalent cations on blood platelet behaviour [proceedings]. (1978) (1)
A story of cooperation and friendship in Europe with good outcomes (2016) (1)
Antiplatelet therapy for stroke prevention (2005) (1)
Paf-Induced Platelet Aggregation in Whole Blood and the Effect of Administering Bn52063 to Man (1987) (1)
O4 Heparins sensitize platelets to responses mediated via both the P27 and the P2Y1 receptor pathways (1999) (1)
Increased platelet activation in renal transplant patients. (1999) (1)
Cyclic Nucleotide Phosphodiesterase Activity and the Platelet Release Reaction (1978) (1)
A method for estimating prostaglandin synthetase activity in blood platelets and the extent of its pharmacological inhibition [proceedings]. (1978) (1)
SEMI‐AUTOMATED TRANSFORMATION TECHNIQUES FROM SINGLE AERIAL PHOTOGRAPHS (2006) (1)
Whole blood and the effect of administering BN 52063 to man (1987) (0)
Correction (2017) (0)
Use of the flow cytometer to measure platelet shape change and fibrinogen binding following platelet activation (1995) (0)
Effects of aspirin and dazoxiben upon the peripheral circulation in man (1984) (0)
Blood relation (1992) (0)
Abstract WP76: Baseline Characteristics of the 3,096 Patients Recruited Into the ‘Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke’ (TARDIS) Trial (2017) (0)
Prostaglandins in vascular disease (1981) (0)
Baseline predictors of on-treatment platelet activity (as P-selectin expression) in patients in the triple aniplatelets for reducing dependency in ischaemic stroke (TARDIS) trial (2018) (0)
HETEROCLITIN D, A COMPONENT OF PLANTS OF THE KADSURA SPECIES INHIBITS PAF-INDUCED PLATELET AGGREGATION, P-SELECTIN EXPRESSION AND PLATELET-LEUCOCYTE CONJUGATE FORMATION (2007) (0)
[Effect of high glucose concentrations on spontaneous aggregation of human blood platelets]. (1988) (0)
Inhibition of prostaglandin and thromboxane synthesis in blood platelets: evaluation of its effect in platelets from healthy individuals and from diabetics (1982) (0)
Platelets-issue number 1. (1990) (0)
EXTRACELLULAR CALCIUM AND PLATELET GLYCOPROTEINS (1987) (0)
Platelets-the Phoenix arises. (1996) (0)
A COMPARISON OF THE ABILITIESOF ACETYLSALICYLICACID, FLURBIPROFENAND INDOMETHACIN TO INHIBITTHE RELEASE REACTION AND PROSTAGLANDIN SYNTHESISIN HUMAN BLOOD PLATELETS (1979) (0)
Abstract TMP109: Remote Platelet Function Testing Using Measurement of P-selectin in Patients in the Triple Antiplatelets for Reducing Dependency in Ischaemic Stroke (TARDIS) Trial (2018) (0)
Interactions Between Different P2Y12 Antagonists (2008) (0)
Feverfew inrheumatoid arthritis: a double blind, placebo controlled study (1989) (0)
A PLASMA FACTOR FROM A PATIENT WITH A BLEEDING TENDENCY CAUSES PLATELET SECRETION IN THE ABSENCE OF EXTRACELLULAR CALCIUM (1987) (0)
Introducing a new type of article for Platelets: Spotlight articles (2010) (0)
Statement of Retraction: Gupta A, Chandra T, Kumar A. “Platelet storage lesion: Current proteomics approach” (2011) (0)
Obituary (2011) (0)
Photofeature: European cardiovascular researchers on holiday and outside of work (2010) (0)
COllagen-induced Platelet Behaviour (1979) (0)
Prostaglandins and Other Lipid Mediators (2010) (0)
Editorial: Cardiovascular & Renal: Numerous approaches to reducing platelet aggregation (1995) (0)
Can the effects of clinical reperfusion fluids on platelet aggregation in vitro predict the effects of administration of such fluids in a clinical study ex vivo? (2003) (0)
Platelets-the end of an era. (1995) (0)
Intra-vascular oxygen delivery by novel perfluorochemical emulsions: potential beneficial effects on platelet aggregation (1997) (0)
Calcium Binding Sites on Human Blood Platelets (1977) (0)
Antiplatelet agents???biological and clinical aspects (1996) (0)
INTERACTIONS BETWEEn PGE2 AND INHIBITORS OF PLATELET AGGREGATION THAT ACT THROUGH cAMP (1987) (0)
Book review. (1994) (0)
P17. Effects of Pluronic?? F-68 on platelet aggregation in human whole blood (1996) (0)
Book review. (1991) (0)
CorrectionP-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist (2004) (0)
AERIAL PHOTO INTERPRETATION OF ENGINEERING AND SOIL SURVEYS (1974) (0)
Prostaglandins and Other Lipid Mediators GE 1 and PGE 2 modify platelet function through different prostanoid receptors (2010) (0)
The Effects of Three Potential Antithromotic Agents on Platelet Activities Ex VNO. (1979) (0)
Call for contributions to the new Methods section in Platelets (2009) (0)
Abstracts of papers presented at the 8th Erfurt Conference on Platelets, 25–28 June 2000, Augustiner-Kloster, Erfurt, Germany (2000) (0)
James G. White MD, 1929–2016 (2017) (0)
A Prospective Study Investigating Changes in Basal Intracellular Free Calcium in Platelets of Normotensive and Hypertensive Primigravidae (1990) (0)
Anticoagulants, Antiplatelets and Thrombolytics, 2nd Edition. (2011) (0)
EFFECTS OF FEVERFEW EXTRACT AND PARTHENOLIDE ON PLATELET SECRETION. (1987) (0)
COMPARISON OF THE EFFECTS OF THE P2Y14 RECEPTOR AGONIST UDP-GLUCOSE AND THE EP3 RECEPTOR AGONIST SULPROSTONE ON PLATELET FUNCTION (2007) (0)
Adenosine Diphosphate Induced Aggregation and Release Reaction in Heparinized Platelet Rich Plasma (1977) (0)
Comparison of the effects of the P2Y12 ADP-receptor antagonist (AR-C69931) and the GPIIb/IIIa antagonist GR 144053F on platelet-leukocyte conjugate formation. (2002) (0)
Platelet Release Reaction - A Predictor of Death Following Myocardial Infarction? (1979) (0)
BLOOD TAURINE AFTER MYOCARDIAL INFARCTION (1987) (0)
Monitoring the Effects of Glycoprotein IIb/IIIa Antagonists using a Whole Blood Assay of Platelet Microaggregation: Comparison with Other Aggregation Methodologies (1999) (0)

This paper list is powered by the following services:

Other Resources About Stan Heptinstall

en.wikipedia.org

What Schools Are Affiliated With Stan Heptinstall?

Stan Heptinstall is affiliated with the following schools:

Image Attributions

Image Source for Stan Heptinstall